




Instance: composition-en-1f96cd88f64662096f991c68963865d4
InstanceOf: CompositionUvEpi
Title: "Composition for baraclude Package Leaflet"
Description:  "Composition for baraclude Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/06/343/003"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1f96cd88f64662096f991c68963865d4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - baraclude"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Baraclude is and what it is used for </li>
<li>What you need to know before you take Baraclude </li>
<li>How to take Baraclude </li>
<li>Possible side effects </li>
<li>How to store Baraclude </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What baraclude is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What baraclude is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Baraclude tablets are anti-viral medicines, used to treat chronic (long term) hepatitis B virus 
(HBV) infection in adults. Baraclude can be used in people whose liver is damaged but still functions 
properly (compensated liver disease) and in people whose liver is damaged and does not function 
properly (decompensated liver disease). </p>
<p>Baraclude tablets are also used to treat chronic (long term) HBV infection in children and 
adolescents aged 2 years to less than 18 years. Baraclude can be used in children whose liver is 
damaged but still functions properly (compensated liver disease). </p>
<p>Infection by the hepatitis B virus can lead to damage to the liver. Baraclude reduces the amount of 
virus in your body, and improves the condition of the liver. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take baraclude"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take baraclude"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Baraclude 
* if you are allergic (hypersensitive) to entecavir or any of the other ingredients of this medicine 
(listed in section 6). </p>
<p>Warning and precautions 
Talk to your doctor or pharmacist before taking Baraclude 
* if you have ever had problems with your kidneys, tell your doctor. This is important because 
Baraclude is eliminated from your body through the kidneys and your dose or dosing schedule 
may need to be adjusted. </p>
<ul>
<li>
<p>do not stop taking Baraclude without your doctor s advice since your hepatitis may worsen 
after stopping treatment. When your treatment with Baraclude is stopped, your doctor will 
continue to monitor you and take blood tests for several months. </p>
</li>
<li>
<p>discuss with your doctor whether your liver functions properly and, if not, what the possible 
effects on your Baraclude treatment may be. </p>
</li>
<li>
<p>if you are also infected with HIV (human immunodeficiency virus) be sure to tell your doctor. 
You should not take Baraclude to treat your hepatitis B infection unless you are taking 
medicines for HIV at the same time, as the effectiveness of future HIV treatment may be 
reduced. Baraclude will not control your HIV infection. </p>
</li>
<li>
<p>taking Baraclude will not stop you from infecting other people with hepatitis B virus 
(HBV) through sexual contact or body fluids (including blood contamination). So, it is 
important to take appropriate precautions to prevent others from becoming infected with HBV. 
A vaccine is available to protect those at risk from becoming infected with HBV. </p>
</li>
<li>
<p>Baraclude belongs to a class of medicines that can cause lactic acidosis (excess of lactic acid 
in your blood) and enlargement of the liver. Symptoms such as nausea, vomiting and stomach 
pain might indicate the development of lactic acidosis. This rare but serious side effect has 
occasionally been fatal. Lactic acidosis occurs more often in women, particularly if they are 
very overweight. Your doctor will monitor you regularly while you are receiving Baraclude. </p>
</li>
<li>
<p>if you have previously received treatment for chronic hepatitis B, please inform your doctor. </p>
</li>
</ul>
<p>Children and adolescents 
Baraclude should not be used for children below 2 years of age or weighing less than 10 kg. </p>
<p>Other medicines and Baraclude 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Baraclude with food and drink 
In most cases you may take Baraclude with or without food. However, if you have had a previous 
treatment with a medicine containing the active substance lamivudine you should consider the 
following. If you were switched over to Baraclude because the treatment with lamivudine was not 
successful, you should take Baraclude on an empty stomach once daily. If your liver disease is very 
advanced, your doctor will also instruct you to take Baraclude on an empty stomach. Empty stomach 
means at least 2 hours after a meal and at least 2 hours before your next meal. 
Children and adolescents (from 2 to less than 18 years of age) can take Baraclude with or without 
food. 
Pregnancy, breast-feeding and fertility 
Tell your doctor if you are pregnant or planning to become pregnant. It has not been demonstrated that 
Baraclude is safe to use during pregnancy. Baraclude must not be used during pregnancy unless 
specifically directed by your doctor. It is important that women of childbearing age receiving 
treatment with Baraclude use an effective method of contraception to avoid becoming pregnant. </p>
<p>You should not breast-feed during treatment with Baraclude. Tell your doctor if you are breast-
feeding. It is not known whether entecavir, the active ingredient in Baraclude, is excreted in human 
breast milk. </p>
<p>Driving and using machines 
Dizziness, tiredness (fatigue) and sleepiness (somnolence) are common side effects which may impair 
your ability to drive and use machines. If you have any concerns consult your doctor. </p>
<p>Baraclude contains lactose 
This medicinal product contains lactose. If you have been told by your doctor that you have an 
intolerance to some sugars, contact your doctor before taking this medicinal product. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take baraclude"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take baraclude"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Not all patients need to take the same dose of Baraclude. </p>
<p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure.  </p>
<p>For adults the recommended dose is either 0.5 mg or 1 mg once daily orally (by mouth). </p>
<p>Your dose will depend on: 
* whether you have been treated for HBV infection before, and what medicine you received. 
* whether you have kidney problems. Your doctor may prescribe a lower dose for you or instruct 
you to take it less often than once a day. 
* the condition of your liver. </p>
<p>For children and adolescents (from 2 to less than 18 years of age), your child's doctor will decide the 
right dose based on your child's weight. The Baraclude oral solution is recommended for patients 
weighing from 10 kg to 32.5 kg.Children weighing at least 32.6 kg may take the oral solution or the 
0.5 mg tablet. All dosing will be taken once daily orally (by mouth). There are no recommendations 
for Baraclude in children less than 2 years of age or weighing less than 10 kg. </p>
<p>Your doctor will advise you on the dose that is right for you. Always take the dose recommended by 
your doctor to ensure that your medicine is fully effective and to reduce the development of resistance 
to treatment. Take Baraclude as long as your doctor has told you. Your doctor will tell you if and when 
you should stop the treatment. </p>
<p>Some patients must take Baraclude on an empty stomach (see Baraclude with food and drink in 
Section 2). If your doctor instructs you to take Baraclude on an empty stomach, empty stomach means 
at least 2 hours after a meal and at least 2 hours before your next meal. </p>
<p>If you take more Baraclude than you should 
Contact your doctor at once. </p>
<p>If you forget to take Baraclude 
It is important that you do not miss any doses. If you miss a dose of Baraclude, take it as soon as 
possible, and then take your next scheduled dose at its regular time. If it is almost time for your next 
dose, do not take the missed dose. Wait and take the next dose at the regular time. Do not take a 
double dose to make up for a forgotten dose. </p>
<p>Do not stop Baraclude without your doctor s advice 
Some people get very serious hepatitis symptoms when they stop taking Baraclude. Tell your doctor 
immediately about any changes in symptoms that you notice after stopping treatment. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Patients treated with Baraclude have reported the following side effects: </p>
<p>Adults 
* common (at least 1 in 100 patients): headache, insomnia (inability to sleep), fatigue (extreme 
tiredness), dizziness, somnolence (sleepiness), vomiting, diarrhoea, nausea, dyspepsia 
(indigestion), and increased blood levels of liver enzymes. 
* uncommon (at least 1 in 1,000 patients): rash, hair loss. 
* rare (at least 1 in 10,000 patients): severe allergic reaction. </p>
<p>Children and adolescents 
The side effects experienced in children and adolescents are similar to those experienced in adults as 
described above with the following difference: 
Very common (at least 1 in 10 patients): low levels of neutrophils (one type of white blood cells, 
which are important in fighting infection). </p>
<p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist or. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store baraclude"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store baraclude"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the bottle, blister or carton after EXP. 
That expiry date refers to the last day of that month. </p>
<p>Blister packs: do not store above 30 C. Store in the original carton. 
Bottle packs: do not store above 25 C. Keep the bottle tightly closed. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Baraclude contains 
* The active substance is entecavir. Each film-coated tablet contains 0.5 mg entecavir. 
* The other ingredients are: 
Tablet core: crospovidone, lactose monohydrate, magnesium stearate, cellulose microcrystalline 
and povidone. 
Tablet coating: hypromellose, macrogol 400, titanium dioxide (E171), and polysorbate (E433). </p>
<p>What Baraclude looks like and contents of the pack 
The film-coated tablets (tablets) are white to off-white and triangular-shaped. They are marked with 
 BMS  on one side and  1611  on the other. Baraclude 0.5 mg film-coated tablets are supplied in 
cartons containing 30 x 1 or 90 x 1 film-coated tablet (in unit-dose blisters) and in bottles containing 
30 film-coated tablets. </p>
<p>Not all pack sizes may be marketed in your country. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Marketing Authorisation Holder: 
Bristol-Myers Squibb Pharma EEIG<br />
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIreland </p>
<p>Manufacturer: 
CATALENT ANAGNI S.R.L. 
Loc. Fontana del Ceraso snc 
Strada Provinciale 12 Casilina, 03012 Anagni (FR) 
Italy </p>
<p>Swords Laboratories  Unlimited Company T/A Bristol-Myers Squibb Pharmaceutical Operations, 
External Manufacturing 
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIreland </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-1f96cd88f64662096f991c68963865d4
InstanceOf: CompositionUvEpi
Title: "Composition for baraclude Package Leaflet"
Description:  "Composition for baraclude Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/06/343/003"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1f96cd88f64662096f991c68963865d4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - baraclude"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Baraclude 
3. Sådan skal du tage Baraclude 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Baraclude tabletter er anti-viral medicin, som anvendes til at behandle kronisk  (vedvarende) 
infektion med hepatitis-B virus (HBV) hos voksne. Baraclude kan anvendes til mennesker, hvis 
lever er skadet, men stadig fungerer ordentligt (kompenseret leversygdom) og til mennesker, hvis lever 
er skadet og ikke fungerer ordentligt (inkompenseret leversygdom). </p>
<p>Baraclude tabletter anvendes også til at behandle kronisk (vedvarende) infektion med HBV hos 
børn og unge i alderen 2-18 år. Baraclude kan anvendes til børn, hvis lever er skadet, men stadig 
fungerer ordentligt (kompenseret leversygdom). </p>
<p>Infektion med hepatitis-B virus kan medføre leverskader. Baraclude mindsker mængden af virus i 
kroppen og forbedrer leverens tilstand. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  baraclude"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  baraclude"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Baraclude </p>
<ul>
<li>hvis du er overfølsom (allergisk) over for entecavir eller et af de øvrige indholdsstoffer i dette 
lægemiddel (angivet i afsnit 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Baraclude </p>
<ul>
<li>
<p>hvis du tidligere har haft problemer med nyrerne, skal du fortælle din læge det. Det er 
vigtigt, fordi Baraclude udskilles gennem nyrerne, og din dosis eller dosisintervallet skal 
tilpasses. </p>
</li>
<li>
<p>du skal ikke holde op med at tage Baraclude uden at have talt med din læge om det først, 
da din hepatitis kan forværres, efter at behandlingen stoppes. Hvis behandlingen med Baraclude 
skal stoppes, vil din læge følge dig og tage blodprøver igennem flere måneder. </p>
</li>
<li>
<p>tal med lægen om din lever fungerer ordentligt, og hvis ikke, find ud af, hvordan det kan 
påvirke din behandling med Baraclude. </p>
</li>
<li>
<p>hvis du også har en hiv-infektion (humant immundefektvirus), skal du sørge for at fortælle det 
til din læge. Du bør ikke tage Baraclude for at behandle din hepatitis-B-infektion, medmindre du 
samtidig også tager medicin mod hiv, idet virkningen af fremtidig hiv-behandling kan blive 
nedsat. Baraclude vil ikke kontrollere din hiv-infektion. </p>
</li>
<li>
<p>selvom du tager Baraclude, kan du stadig smitte andre med hepatitis-B virus (HBV) 
gennem seksuel kontakt eller kropsvæsker (fx blod). Så det er vigtigt, at du overholder relevante 
forholdsregler for at undgå at smitte andre med HBV. Det er muligt at blive vaccineret mod 
HBV. </p>
</li>
<li>
<p>Baraclude tilhører en gruppe medicin, der kan forårsage lactacidose (ophobning af 
mælkesyre i blodet) og forstørret lever. Kvalme, opkastning og mavesmerter kan være tegn på 
udvikling af lactacidose. Denne sjældne, men alvorlige bivirkning har i nogle tilfælde været 
dødelig. Kvinder har større risiko for lactacidose, specielt hvis de er meget overvægtige. Lægen 
vil jævnligt kontrollere dig, mens du tager Baraclude. </p>
</li>
<li>
<p>tal med lægen, hvis du tidligere har modtaget behandling for kronisk hepatitis B. </p>
</li>
</ul>
<p>Børn og unge 
Baraclude bør ikke anvendes til børn under 2 år eller børn, der vejer under 10 kg. </p>
<p>Brug af anden medicin sammen med Baraclude 
Fortæl altid lægen eller apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt anden 
medicin eller planlægger at bruge anden medicin. Dette gælder også medicin, som ikke er købt på 
recept, f.eks. naturlægemidler og vitaminer og mineraler. </p>
<p>Baraclude sammen med mad og drikke 
De fleste kan tage Baraclude med eller uden mad. Hvis du tidligere har fået medicin, der indeholder 
lamivudin, skal du dog være opmærksom på følgende: Hvis du er skiftet til Baraclude, fordi 
behandlingen med lamivudin ikke virkede, skal du tage Baraclude på tom mave, én gang dagligt. Hvis 
din leversygdom er meget fremskreden, vil lægen ligeledes vejlede dig i, at du skal tage Baraclude på 
tom mave. Tom mave betyder mindst 2 timer efter et måltid og mindst 2 timer før det næste måltid. 
Børn og unge (fra 2-18 år) kan tage Baraclude med eller uden mad. </p>
<p>Graviditet, amning og frugtbarhed 
Fortæl det til lægen, hvis du er gravid, eller hvis du planlægger at blive gravid. Det vides ikke, om det 
er sikkert at bruge Baraclude under graviditet. Baraclude må ikke anvendes under graviditet undtagen, 
hvis lægen har ordineret det til dig. Det er vigtigt, at frugtbare kvinder, som er i behandling med 
Baraclude, anvender effektiv svangerskabsforebyggelse for at forhindre graviditet. </p>
<p>Du må ikke amme, mens du er i behandling med Baraclude. Fortæl det til lægen, hvis du ammer. Det 
vides ikke om entecavir, der er det aktive indholdsstof i Baraclude, udskilles i mælken. </p>
<p>Trafik og arbejdssikkerhed 
Svimmelhed, voldsom træthed og søvnighed er almindelige bivirkninger, som kan påvirke evnen til at 
køre bil, motorcykel eller cykle eller arbejde med værktøj eller maskiner. Hvis du har spørgsmål, kan 
du kontakte lægen. </p>
<p>Baraclude indeholder lactose 
Kontakt lægen, før du tager denne medicin, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage baraclude"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage baraclude"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dosis af Baraclude er ikke den samme til alle patienter. </p>
<p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet.  </p>
<p>Til voksne er den anbefalede dosis 0,5 mg eller 1 mg én gang dagligt oralt (igennem munden). </p>
<p>Din dosis afhænger af: </p>
<ul>
<li>
<p>om du tidligere er behandlet for HBV-infektion, og hvilken medicin du fik. </p>
</li>
<li>
<p>om du har nyreproblemer. Lægen kan vælge at give dig en lavere dosis eller vejlede dig i at tage 
medicinen mindre end en gang dagligt. </p>
</li>
<li>
<p>tilstanden af din lever. </p>
</li>
</ul>
<p>Til børn og unge (fra 2-18 år) vil barnets læge fastsætte den korrekte dosis ud fra barnets vægt. 
Baraclude oral opløsning anbefales til patienter, der vejer fra 10-32,5 kg.Børn, der vejer mindst 
32,6 kg kan bruge den orale opløsning eller 0,5 mg tabletten. Alle doseringer tages én gang dagligt 
oralt (igennem munden). Der er ingen dosisanbefalinger for Baraclude til børn under 2 år eller børn, 
der vejer under 10 kg. </p>
<p>Lægen vil rådgive dig om, hvilken dosis, der er bedst for dig. Tag altid den dosis, lægen anbefaler for 
at være sikker på, at medicinen virker helt som den skal og for at mindske udviklingen af resistens. 
Tag Baraclude lige så længe som lægen har foreskrevet. Lægen vil give dig besked om, hvorvidt du 
skal afslutte behandingen, og hvornår du skal afslutte behandlingen. </p>
<p>Nogle patienter skal tage Baraclude på tom mave (se Baraclude sammen med mad og drikke i afsnit 
2). Hvis lægen har sagt, at du skal tage Baraclude på tom mave, betyder det mindst 2 timer efter et 
måltid og mindst 2 timer før næste måltid. </p>
<p>Hvis du har taget for meget Baraclude 
skal du straks kontakte lægen. </p>
<p>Hvis du har glemt at tage Baraclude 
Det er vigtigt, at du ikke springer en dosis over. Hvis du glemmer at tage en dosis af Baraclude, skal 
du tage den så hurtigt som muligt, og herefter tage næste dosis til sædvanlig tid. Hvis det næsten er tid 
til næste dosis, skal du ikke tage den glemte dosis, men vente og tage næste dosis til sædvanlig tid. Du 
må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Du må ikke holde op med at tage Baraclude uden at have talt med lægen 
Nogle mennesker får meget alvorlige leversymptomer, når de holder op med at tage Baraclude. Hvis 
du bemærker ændringer i symptomer, efter at behandlingen er stoppet, skal du straks fortælle det til 
lægen. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.  </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Patienter behandlet med Baraclude har indberettet følgende bivirkninger: </p>
<p>Voksne </p>
<ul>
<li>
<p>almindelige (kan forekomme hos mindst 1 ud af 100 patienter): hovedpine, søvnløshed, voldsom 
træthed, svimmelhed, søvnighed, opkastning, diarré, kvalme, fordøjelsesbesvær og forhøjet 
indhold af leverenzymer i blodet. </p>
</li>
<li>
<p>ikke almindelige (kan forekomme hos mindst 1 ud af 1.000 patienter): udslæt, hårtab.  </p>
</li>
<li>
<p>sjældne (kan forekomme hos mindst 1 ud af 10.000 patienter): alvorlig allergisk reaktion. </p>
</li>
</ul>
<p>Børn og unge 
De bivirkninger, der er set hos børn og unge, svarer til dem, der er set hos voksne som beskrevet 
ovenfor med følgende forskel: 
Meget almindelige (kan forekomme hos mindst 1 ud af 10 patienter): lave niveauer af neutrofiler (en 
type hvide blodlegemer, der er vigtige til bekæmpelse af infektion). </p>
<p>Tal med lægen eller apotekspersonalet, hvis du får bivirkninger, herunder bivirkninger, som ikke 
fremgår af denne indlægsseddel. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar dette lægemiddel utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på beholderen, blisteren eller kartonen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Blisterpakning: må ikke opbevares ved temperaturer over 30 °C. Opbevares i originalemballagen. 
Beholdere: må ikke opbevares ved temperaturer over 25 °C. Beholderen skal holdes tæt tillukket. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Baraclude indeholder: </p>
<ul>
<li>
<p>Aktivt stof: entecavir. Hver filmovertrukken tablet indeholder 0,5 mg entecavir. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: 
Tabletkerne: crospovidon, lactosemonohydrat, magnesiumstearat, cellulose, mikrokrystallinsk 
og povidon. 
Tabletovertræk: hypromellose, macrogol 400, titandioxid (E171) og polysorbat 80 (E433). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
De filmovertrukne tabletter er hvide til grålighvide og trekantede. De er mærkede “BMS" på den ene 
side og “1611" på den anden. Baraclude 0,5 mg filmovertrukne tabletter fås i æsker med 30 x 1 eller 
90 x 1 filmovertrukket tablet (enkeltdosis-blistere) og i beholdere med 30 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser markedsføres nødvendigvis i dit land. </p>
<p>Indehaver af markedsføringstilladelse og fremstiller 
Indehaver af markedsføringstilladelsen: 
Bristol-Myers Squibb Pharma EEIG<br />
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIrland </p>
<p>Fremstiller: 
CATALENT ANAGNI S.R.L. 
Loc. Fontana del Ceraso snc 
Strada Provinciale 12 Casilina, 03012 Anagni (FR) 
Italien </p>
<p>Swords Laboratories Unlimited Company T/A Bristol-Myers Squibb Pharmaceutical Operations, 
External Manufacturing 
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIrland </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. </p>
<p>Indlægsseddel: Information til brugeren </p>
<p>Baraclude 1 mg filmovertrukne tabletter 
entecavir </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. </p>
<ul>
<li>
<p>Gem indlægssedlen. Du kan få brug for at læse den igen. </p>
</li>
<li>
<p>Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. </p>
</li>
<li>
<p>Lægen har ordineret Baraclude til dig personligt. Lad derfor være med at give medicinen til 
andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har. </p>
</li>
<li>
<p>Kontakt lægen eller apotekspersonalet, hvis du får bivirkninger, herunder bivirkninger, som ikke 
er nævnt i denne indlægsseddel. Se afsnit 4. Se den nyeste indlægsseddel på www.indlaegsseddel.dk </p>
</li>
</ul> </div>"""      





                    
Instance: bundlepackageleaflet-en-1f96cd88f64662096f991c68963865d4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for baraclude Package Leaflet for language en"
Description: "ePI document Bundle for baraclude Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-1f96cd88f64662096f991c68963865d4"
* entry[0].resource = composition-en-1f96cd88f64662096f991c68963865d4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp1f96cd88f64662096f991c68963865d4"
* entry[=].resource = mp1f96cd88f64662096f991c68963865d4
                            
                    
Instance: bundlepackageleaflet-da-1f96cd88f64662096f991c68963865d4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for baraclude Package Leaflet for language da"
Description: "ePI document Bundle for baraclude Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-1f96cd88f64662096f991c68963865d4"
* entry[0].resource = composition-da-1f96cd88f64662096f991c68963865d4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp1f96cd88f64662096f991c68963865d4"
* entry[=].resource = mp1f96cd88f64662096f991c68963865d4
                            
                    



Instance: mp1f96cd88f64662096f991c68963865d4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Baraclude 0.5 mg film-coated tablets"
Description: "Baraclude 0.5 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/06/343/003"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Baraclude 0.5 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 1f96cd88f64662096f991c68963865d4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "baraclude"

* status = #current
* mode = #working

* title = "List of all ePIs associated with baraclude"

* subject = Reference(mp1f96cd88f64662096f991c68963865d4)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#baraclude "baraclude"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-1f96cd88f64662096f991c68963865d4) // baraclude en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-1f96cd88f64662096f991c68963865d4) // baraclude da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-1f96cd88f64662096f991c68963865d4
InstanceOf: List

* insert 1f96cd88f64662096f991c68963865d4ListRuleset
    